{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:56:00Z","timestamp":1793199360985,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Critical limb ischemia (CLI) is associated with a high risk of limb amputation. It has been shown that cell therapy is safe and has beneficial effects on ischemic clinical symptoms in patients with CLI. The aim of this study was to further investigate the outcomes of intramuscular injection of autologous bone-marrow mononuclear cells (BM-MNCs) in a long-term follow-up period in atherosclerotic peripheral arterial disease (PAD) patients who have no optional therapy. This study was a retrospective and observational study that was carried out to evaluate long-term clinical outcomes in 42 lower limbs of 30 patients with atherosclerotic PAD who underwent BM-MNC implantation. The median follow-up period was 9.25 (range, 6\u201316) years. The overall amputation-free rates were 73.0% at 5 years after BM-MNC implantation and 70.4% at 10 years in patients with atherosclerotic PAD. The overall amputation-free rates at 5 years and at 10 years after implantation of BM-MNCs were significantly higher in atherosclerotic PAD patients than in internal controls and historical controls. There were no significant differences in amputation rates between the internal control group and historical control group. The rate of overall survival was not significantly different between the BM-MNC implantation group and the historical control group. Implantation of autologous BM-MNCs is feasible for a long-term follow-up period in patients with CLI who have no optional therapy.<\/jats:p>","DOI":"10.1038\/s41598-019-44176-5","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T10:04:48Z","timestamp":1558519488000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Review of the Long-term Effects of Autologous Bone-Marrow Mononuclear Cell Implantation on Clinical Outcomes in Patients with Critical Limb Ischemia"],"prefix":"10.1038","volume":"9","author":[{"given":"Farina Mohamad","family":"Yusoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Kajikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5109-7805","authenticated-orcid":false,"given":"Shinji","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Maruhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moniruddin","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Noma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7838-1494","authenticated-orcid":false,"given":"Ayumu","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuki","family":"Kihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taijiro","family":"Sueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihito","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,22]]},"reference":[{"key":"44176_CR1","doi-asserted-by":"publisher","first-page":"e001946","DOI":"10.1161\/CIRCOUTCOMES.108.775247","volume":"9","author":"S Kinlay","year":"2016","unstructured":"Kinlay, S. Management of critical limb ischemia. Circ Cardiovasc Interv. 9, e001946, https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.108.775247 (2016).","journal-title":"Circ Cardiovasc Interv."},{"key":"44176_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06597-y","volume":"7","author":"Y Higashi","year":"2017","unstructured":"Higashi, Y. et al. Two-year follow-up of vascular events in peripheral arterial disease treated with antiplatelet agents: a prospective observational multicenter cohort study (SEASON). Scientific Reports 7, 6095, https:\/\/doi.org\/10.1038\/s41598-017-06597-y (2017).","journal-title":"Scientific Reports"},{"issue":"Suppl 1","key":"44176_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejvs.2006.09.024","volume":"33","author":"L Norgren","year":"2007","unstructured":"Norgren, L. et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J. Vasc Endovasc Surg. 33(Suppl 1), 1\u201375, https:\/\/doi.org\/10.1016\/j.ejvs.2006.09.024 (2007).","journal-title":"Eur J. Vasc Endovasc Surg."},{"key":"44176_CR4","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1161\/CIR.0b013e31822e80c3","volume":"124","author":"2011 Writing Group Members, 2005 Writing Committee Members & ACCF\/AHA Task Force","year":"2011","unstructured":"2011 Writing Group Members, 2005 Writing Committee Members & ACCF\/AHA Task Force. 2011 ACCF\/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation 124, 2020\u20132045, https:\/\/doi.org\/10.1161\/CIR.0b013e31822e80c3 (2011).","journal-title":"Circulation"},{"key":"44176_CR5","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/S0140-6736(05)67704-5","volume":"366","author":"DJ Adam","year":"2005","unstructured":"Adam, D. J. et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. The Lancet 366, 1925\u20131934, https:\/\/doi.org\/10.1016\/S0140-6736(05)67704-5 (2005).","journal-title":"The Lancet"},{"key":"44176_CR6","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/j.jvs.2015.07.065","volume":"62","author":"AM Abu Dabrh","year":"2015","unstructured":"Abu Dabrh, A. M. et al. The natural history of untreated severe or critical limb ischemia. J. Vasc Surg. 62, 1642\u20131651, https:\/\/doi.org\/10.1016\/j.jvs.2015.07.065 (2015).","journal-title":"J. Vasc Surg."},{"key":"44176_CR7","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1161\/CIRCULATIONAHA.105.593442","volume":"114","author":"BA Golomb","year":"2006","unstructured":"Golomb, B. A., Dang, T. T. & Criqui, M. H. Peripheral arterial disease: morbidity and mortality implications. Circulation 114, 688\u2013699, https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.593442 (2006).","journal-title":"Circulation"},{"key":"44176_CR8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1053\/ejvs.1999.1052","volume":"19","author":"WB Campbell","year":"2000","unstructured":"Campbell, W. B., Verfaillie, P., Ridler, B. M. & Thompson, J. F. Non-operative treatment of advanced limb ischaemia: the decision for palliative care. Eur J. Vasc Endovasc Surg. 19, 246\u2013249, https:\/\/doi.org\/10.1053\/ejvs.1999.1052 (2000).","journal-title":"Eur J. Vasc Endovasc Surg."},{"key":"44176_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1161\/CIRCOUTCOMES.108.775247","volume":"1","author":"EM Mahoney","year":"2008","unstructured":"Mahoney, E. M. et al. One- year costs in patients with a history of or at risk for atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes 1, 38\u201345, https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.108.775247 (2008).","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"44176_CR10","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1177\/0309364612441489","volume":"36","author":"RW Jordan","year":"2012","unstructured":"Jordan, R. W., Marks, A. & Higman, D. The cost of major lower limb amputation: a 12-year experience. Prosthetics and Orthotics International 36, 430\u2013434, https:\/\/doi.org\/10.1177\/0309364612441489 (2012).","journal-title":"Prosthetics and Orthotics International"},{"key":"44176_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0140-6736(02)09670-8","volume":"360","author":"E Tateishi-Yuyama","year":"2002","unstructured":"Tateishi-Yuyama, E. et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomized controlled trial. The Lancet 360, 427\u2013435, https:\/\/doi.org\/10.1016\/S0140-6736(02)09670-8 (2002).","journal-title":"The Lancet"},{"key":"44176_CR12","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.ahj.2008.06.025","volume":"156","author":"S Matoba","year":"2008","unstructured":"Matoba, S. et al. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J. 156, 1010\u20131018, https:\/\/doi.org\/10.1016\/j.ahj.2008.06.025 (2008).","journal-title":"Am Heart J."},{"key":"44176_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.atherosclerosis.2009.08.033","volume":"209","author":"GP Fadini","year":"2010","unstructured":"Fadini, G. P., Agostini, C. & Avogaro, A. Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis 209, 10\u201317, https:\/\/doi.org\/10.1016\/j.atherosclerosis.2009.08.033 (2010).","journal-title":"Atherosclerosis"},{"key":"44176_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jdiacomp.2011.11.007","volume":"26","author":"A Ozturk","year":"2012","unstructured":"Ozturk, A. et al. Therapeutical potential of autologous peripheral blood mononuclear cell transplantation in patients with type 2 diabetic critical limb ischemia. J. Diabetes Complications 26, 29\u201333, https:\/\/doi.org\/10.1016\/j.jdiacomp.2011.11.007 (2012).","journal-title":"J. Diabetes Complications"},{"key":"44176_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-017-1153-4","volume":"15","author":"M Samura","year":"2017","unstructured":"Samura, M. et al. Therapeutic strategies for cell-based neovascularization in critical limb ischemia. J. Transl Med. 15, 49, https:\/\/doi.org\/10.1186\/s12967-017-1153-4 (2017).","journal-title":"J. Transl Med."},{"key":"44176_CR16","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.ejvs.2015.08.018","volume":"50","author":"SM Peeters Weem","year":"2015","unstructured":"Peeters Weem, S. M., Teraa, M., de Borst, G. J., Verhaar, M. C. & Moll, F. L. Bone marrow derived cell therapy in critical limb ischemia: A Meta-analysis of Randomized Placebo Controlled Trials. Eur J. Vasc Endovasc Surg. 50, 775\u2013783, https:\/\/doi.org\/10.1016\/j.ejvs.2015.08.018 (2015).","journal-title":"Eur J. Vasc Endovasc Surg."},{"key":"44176_CR17","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1253\/circj.CJ-17-0045","volume":"81","author":"B Pignon","year":"2017","unstructured":"Pignon, B. et al. Autologous bone marrow mononuclear cell implantation and its impact on the outcome of patients with critical limb ischemia: results of a randomized, double-blind, placebo-controlled trial. Circ J. 81, 1713\u20131720, https:\/\/doi.org\/10.1253\/circj.CJ-17-0045 (2017).","journal-title":"Circ J."},{"key":"44176_CR18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ebiom.2018.08.038","volume":"35","author":"Z Dong","year":"2018","unstructured":"Dong, Z. et al. Purified CD34+ cells versus peripheral blood mononuclear cells in the treatment of angiitis-induced no-option critical limb ischaemia: 12-Month results of a prospective randomised single-blinded non-inferiority trial. EBioMedicine 35, 46\u201357, https:\/\/doi.org\/10.1016\/j.ebiom.2018.08.038 (2018).","journal-title":"EBioMedicine"},{"key":"44176_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1161\/CIRCINTERVENTIONS.110.955724","volume":"4","author":"N Idei","year":"2011","unstructured":"Idei, N. et al. Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia: a comparison of atherosclerotic peripheral arterial disease and buerger disease. Circ Cardiovasc Interv. 4, 15\u201325, https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.110.955724 (2011).","journal-title":"Circ Cardiovasc Interv."},{"key":"44176_CR20","doi-asserted-by":"publisher","first-page":"H886","DOI":"10.1152\/ajpheart.00142.2006","volume":"291","author":"M Takahashi","year":"2006","unstructured":"Takahashi, M. et al. Cytokine produced by bone marrow cells can contribute to functional improvement of the infracted heart by protecting cardiomyocytes from ischemic injury. Am J Physiol Heart Circ Physiol. 291, H886\u2013893, https:\/\/doi.org\/10.1152\/ajpheart.00142.2006 (2006).","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"44176_CR21","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1161\/01.CIR.103.6.897","volume":"103","author":"S Shintani","year":"2001","unstructured":"Shintani, S. et al. Augmentation of postnatal neovascularization with autologous bone marrow implantation. Circulation 103, 897\u2013903, https:\/\/doi.org\/10.1161\/01.CIR.103.6.897 (2001).","journal-title":"Circulation"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-44176-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-44176-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-44176-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T09:50:09Z","timestamp":1671270609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-44176-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,22]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["44176"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-44176-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,22]]},"assertion":[{"value":"7 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"7711"}}